Try our Advanced Search for more refined results

Picone v. Shire U.S. Inc. et al (Indirect Purchaser Antitrust Class Action)

  1. November 09, 2021

    Attys Want $1.8M Cut Of $3M ADHD Antitrust Settlement

    Attorneys from three firms asked a Massachusetts federal judge Monday for fees and costs totaling more than $1.8 million — or about 61% — of a nearly $3 million settlement to be paid by Takeda Pharmaceutical unit Shire and fellow drugmaker Actavis to resolve an antitrust suit.

  2. August 10, 2021

    Shire Pays $1.9M, Boosting ADHD Med Antitrust Deal To $3M

    Shire has inked a $1.9 million deal with a proposed class of parents and caregivers in antitrust litigation over attention deficit hyperactivity disorder medication Intuniv, rounding out a $3 million settlement that it will pay alongside fellow drugmaker Actavis.

  3. May 25, 2021

    Actavis Inks $1.1M Deal In ADHD Medication Antitrust Suit

    A proposed class of parents and caregivers who've accused Actavis of violating antitrust laws by delaying alternatives to its attention deficit hyperactivity disorder medication Intuniv have asked a Massachusetts federal judge to preliminarily approve a $1.1 million settlement with the drugmaker.

  4. September 11, 2020

    ADHD Med Buyers Can't Yet Appeal Class Cert. Denial

    A First Circuit panel has denied a bid by consumers to immediately appeal a Massachusetts federal court's refusal to certify their class in an antitrust suit alleging Shire and Actavis delayed alternatives for Intuniv, a medication for attention deficit hyperactivity disorder.

  5. June 08, 2020

    Judge Says Cert. Unlikely For Parent ADHD Med Buyers

    Parents who say they overpaid for their children's ADHD medications can't pause their antitrust suit against Actavis and Shire while they appeal the court's decision to deny them class certification, a Massachusetts federal judge ruled Monday.

  6. June 03, 2020

    Pharmacy Chain Says It Can Rep Class If Lead Is DQ'd

    A Midwest pharmacy chain said Tuesday that it's ready to fill in as head of a direct purchaser class accusing Actavis and Shire of illegally delaying the sale of a generic version of Shire's ADHD medication Intuniv if the pharmaceutical companies manage to decertify the class's current named plaintiff.

  7. November 06, 2019

    No Class Cert. Redo For ADHD Drug Buyers In Antitrust Suit

    A Massachusetts federal judge refused Wednesday to reconsider her denial of class certification to consumers accusing pharmaceutical companies Actavis and Shire of illegally delaying the sale of a generic version of Shire's ADHD medication Intuniv, finding the buyers still undone by a large group of uninjured buyers.

  8. September 24, 2019

    Rochester Drug To Lead ADHD Generic Delay Class

    A Massachusetts federal judge tapped wholesaler Rochester Drug Co-Operative on Tuesday to lead a class alleging that pharmaceutical companies Shire and Actavis conspired to delay the entry of a generic form of Shire's ADHD drug Intuniv, despite Rochester's criminal problems over opioid sales.

  9. August 21, 2019

    ADHD Drug Indirect Purchasers Lose Antitrust Class Cert. Bid

    A Massachusetts federal judge on Wednesday refused to grant class certification to two classes of parents and caretakers accusing the pharmaceutical companies Actavis and Shire of antitrust violations, saying they delayed sale of the ADHD medication Intuniv, causing consumers to pay inflated prices.

  10. July 26, 2019

    Opioid Seller Seeks To Lead Antitrust Class Despite Charges

    Pharmaceutical distributor Rochester Drug Co-Operative, which admitted to unlawful opioid sales earlier this year, argued in Boston federal court Friday that it is reformed and can dutifully serve as a class representative in an antitrust pay-for-delay suit over the sales of ADHD medication Intuniv.